(GOG 3005) A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The primary objective of the study is to evaluate whether progression-free survival (PFS) is prolonged when veliparib is added to standard latinum-based chemotherapy and then continued as maintenance (Arm 3 versus Arm 1). Progression-free survival as the primary study endpoint will be evaluated in both the whole subject population, as well as a more selective cohort of subjects with -deficient tumors (gBRCA and/or sBRCA). Secondary objectives include overall survival (OS) (Arm 3 versus Arm 1, and Arm 2 versus Arm 1), safety of all three arms, and disease related symptom (DRS) scores (Arm 3 versus Arm 1 and Arm 2 versus Arm 1) in both the whole population and 5RC4-deficient population.
Study Number: 

PH 272715

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.